Trial · NCT02465359
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Relapse of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms | Immune Globulin Subcutaneous (Human) | withdrew prematurely | 3 | Participants | |
| Relapse of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms | Immune Globulin Subcutaneous (Human) | completed study | 12 | Participants | |
| Mean Change in Short Form 36 (SF-36) Domain: Physical Functioning Between Week 24 and Screening | Immune Globulin Subcutaneous (Human) | 0 | 95% Confidence Interval -0.12 to 0.12 | score on a scale | |
| Mean Change in Inflammatory Rasch-built Overall Disability Scale (I-RODS) From Screening to Week 24 | Immune Globulin Subcutaneous (Human) | -1.5 | 95% Confidence Interval -4.6 to 1.6 | units on a scale | |
| Mean Change in Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI) Between Week 24 and Screening | Immune Globulin Subcutaneous (Human) | -4.3 | 95% Confidence Interval -7.7 to -0.9 | units on a scale | |
| Treatment Satisfaction Questionnaire for Medication (TSQM) | Immune Globulin Subcutaneous (Human) | 10.3 | 95% Confidence Interval 4.3 to 16.2 | units on a scale | |
| Mean Change in Short Form 36 Domain: Role Limitations-physical Between Screening and Week 24 | Immune Globulin Subcutaneous (Human) | 0.24 | 95% Confidence Interval 0.03 to 0.46 | score on a scale | |
| Mean Change in Short Form 36 Domain: Role Limitations - Emotional (Between Week 24 and Screening) | Immune Globulin Subcutaneous (Human) | -0.01 | 95% Confidence Interval -0.27 to 0.24 | score on a scale | |
| Mean Change in Short Form 36 Domain: Energy/Fatigue Between Screening and Week 24 | Immune Globulin Subcutaneous (Human) | 0.09 | 95% Confidence Interval 0.00 to 0.18 | score on a scale | |
| Mean Change in Short Form 36 Domain: Emotional Well-being Between Screening and 24 Weeks | Immune Globulin Subcutaneous (Human) | 0.03 | 95% Confidence Interval -0.04 to 0.09 | score on a scale | |
| Mean Change in Short Form 36 Domain: Social Functioning Between Screening and Week 24 | Immune Globulin Subcutaneous (Human) | 0.06 | 95% Confidence Interval -0.07 to 0.19 | score on a scale | |
| Mean Change in Short Form 36 Domain: Pain Between Screening and 24 Weeks | Immune Globulin Subcutaneous (Human) | 0.08 | 95% Confidence Interval 0.00 to 0.16 | score on a scale | |
| Mean Change in Short Form 36 Domain General Health Between Screening and Week 24 | Immune Globulin Subcutaneous (Human) | 0.01 | 95% Confidence Interval -0.07 to 0.10 | score on a scale | |
| Mean Change in Limb Motor Strength Testing (LMST) Over 24 Weeks | Immune Globulin Subcutaneous (Human) | 5.6 | 95% Confidence Interval 2.3 to 8.9 | pounds | |
| Mean Change in Timed 25-foot Walk (T25-FW) Between Screening and Week 24 | Immune Globulin Subcutaneous (Human) | -1.0 | 95% Confidence Interval -2.9 to 0.8 | seconds |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02465359/results